Displaying drugs 101 - 125 of 650 in total
Dostarlimab
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. …
Matched Categories: … CD11a-directed Antibody Interactions ... CD11a-directed Humanized IgG1 Antibody …
Matched Categories: … CD11a-directed Antibody Interactions ... CD11a-directed Humanized IgG1 Antibody …
Rozanolixizumab
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody ... positive for the anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody …
Obiltoxaximab
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Approved
Matched Description: … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of ... Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis …
Matched Categories: … Anthrax Protective Antigen-directed Antibody ... Anthrax Protective Antigen-directed Antibody Interactions …
Matched Categories: … Anthrax Protective Antigen-directed Antibody ... Anthrax Protective Antigen-directed Antibody Interactions …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese …
Sacituzumab govitecan
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent ... sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Zilucoplan
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Abatacept
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Categories: … CD80-directed Antibody Interactions ... CD86-directed Antibody Interactions …
Etanercept
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1....
Approved
Investigational
Eculizumab
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Description: … Eculizumab is a monoclonal antibody that targets complement protein C5. …
Faricimab
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … [A225985, A225990, A225995] Faricimab is an IgG1-derived bispecific antibody capable of simultaneously …
Antithymocyte immunoglobulin (rabbit)
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Description: … Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for …
Matched Categories: … Antibody-Surface Protein Interactions …
Matched Categories: … Antibody-Surface Protein Interactions …
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Ligand-1-directed Antibody Interactions …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Ligand-1-directed Antibody Interactions …
Avelumab
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Ligand-1-directed Antibody Interactions …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Ligand-1-directed Antibody Interactions …
Idarucizumab
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype …
Matched Categories: … Humanized Monoclonal Antibody Fragment …
Matched Categories: … Humanized Monoclonal Antibody Fragment …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows …
Certolizumab pegol
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Description: … Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha ... The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity ... fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody …
Sotrovimab
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Description: … Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV …
Melphalan flufenamide
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Hepatitis B Vaccine (Recombinant)
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada.
The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Ansuvimab
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Categories: … Zaire Ebolavirus Glycoprotein-directed Antibody …
Sulesomab
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Description: … Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes …
Ixekizumab
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has...
Approved
Investigational
Matched Description: … Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin …
Palivizumab
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains...
Approved
Investigational
Matched Description: … Synagis is a composite of human (95%) and murine (5%) antibody sequences. ... Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Displaying drugs 101 - 125 of 650 in total